ClinicalTrials.gg
CompletedNCT00305448FINDER IUpdated Feb 15, 2012Results posted

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

A Phase 2 interventional study of Fulvestrant and Fulvestrant in Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 35 sites in Japan. Open to female participants. Per ClinicalTrials.gov, last updated 2012-02-15.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
36th of 94
143 · median 71
Started
2006
with 4 others
Phase 2
59 of 95
8 open now
Registered
20th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 36th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 20th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.

03

Conditions studied

  • Advanced Breast Cancer
  • Metastatic Breast Cancer

Keywords

  • oncology
  • cancer
  • breast cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor
  • Requiring hormonal treatment
  • women defined as a woman who has stopped having menstrual periods

Exclusion criteria

Exclusion Criteria:

  • Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced breast cancer
  • Treatment with more than one previous regimen of endocrine therapy for advanced breast cancer
  • An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    1

    Fulvestrant 250 mg intramuscular injection

    Drug: Fulvestrant

  • Experimental
    2

    Fulvestrant 250mg (Plus 250mg Loading Regimen)

    Drug: Fulvestrant

  • Experimental
    3

    Fulvestrant 500 mg

    Drug: Fulvestrant

Interventions

  • 250 intramuscular injection

    Also known as: Faslodex, ZD9238

  • 500 mg intramuscular injection

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization

    Time frame: baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)

Secondary outcomes

  1. Time to Progression (TTP)

    Time (in days) from randomization until objective disease progression or death (in the absence of objective progression). RECIST tumour assessments carried out every 12 weeks from randomization (+/- 2 weeks) until data cut-off on 19th March 2008.

    Time frame: every 12 weeks from randomization (+/- 2 weeks) until data cut-off (19th march 2008)

  2. Duration of Response (DoR)

    Time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who achieved a confirmed Complete Response or confirmed Partial Response.

    Time frame: RECIST tumour assessments carried out every 12 weeks from randomisation (+/- 2 weeks) until data cut-off on19th March 2008.

  3. Clinical Benefit Rate (CBR)

    A Clinical Benefit (CB) responder is defined as a patient having a best overall response of Complete response (CR), Partial Response (PR) or Stable disease (SD) provided SD (or better) was present = 154 days from randomization (ie SD = 24 weeks with the 2 week RECIST assessment time window allowed). The Clinical Benefit Rate is the percentage of patients with CB.

    Time frame: every 12 weeks(+/- 2 weeks) from randomization to data up to data cut-off, 19th March 2008.

  4. Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body

    The measure of dispersion for mean population clearance is based on the estimated inter-individual variance

    Time frame: Baseline to 12 weeks

  5. Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes

    The measure of dispersion for volume of distribution is based on the inter-individual variance estimated for the apparent volume of plasma into which Fulvestrant distributes

    Time frame: Baseline to 12 weeks

07

Results

Posted Aug 29, 2011

Participant flow

Postmenopausal women with oestrogen receptor positive advanced breast cancer progressing or relapsing after previousendocrine therapy were randomized between 7th March 2006 and 4th September 2007. The trial was conducted in Japan only. One patient randomised to Fulvestrant 500mg was not dosed, so the Safety population has 46 patients for that arm.

Participant flow — Overall Study
MilestoneFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Started455147
Completed141714
Not completed313433
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject201
Withdrew: Adverse event101
Withdrew: Disease progression273128
Withdrew: Subjective disease progression122
Withdrew: Tumor marker elevation001

Outcome measures

PrimaryObjective Response Rate (ORR)

An objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). A patient has best overall response of CR if she had overall response of CR or PR on one visit and met the confirmation criteria per RECIST. ORR is defined as percentage of patients with objective response. Each patient with measurable disease at baseline was assessed for OR from the sequence of Response Evaluation Criteria in Solid Tumors (RECIST) scan data up to data cut-off. RECIST scans were performed every 12 weeks (+/- 2weeks) from randomization

Time frame:
baseline and every 12 weeks (+/- 2weeks) from randomization data up to data cut-off (19th march 2008)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Objective Response Rate (ORR)11.117.610.6
SecondaryTime to Progression (TTP)

Time (in days) from randomization until objective disease progression or death (in the absence of objective progression). RECIST tumour assessments carried out every 12 weeks from randomization (+/- 2 weeks) until data cut-off on 19th March 2008.

Time frame:
every 12 weeks from randomization (+/- 2 weeks) until data cut-off (19th march 2008)
Reported as:
Median · days
Time to Progression (TTP)
daysFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Time to Progression (TTP)169 (30 to 508)211 (0 to 426)169 (0 to 590)
SecondaryDuration of Response (DoR)

Time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who achieved a confirmed Complete Response or confirmed Partial Response.

Time frame:
RECIST tumour assessments carried out every 12 weeks from randomisation (+/- 2 weeks) until data cut-off on19th March 2008.
Reported as:
Number · Time (Days) - using Kaplan-Meier method

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate (CBR)

A Clinical Benefit (CB) responder is defined as a patient having a best overall response of Complete response (CR), Partial Response (PR) or Stable disease (SD) provided SD (or better) was present = 154 days from randomization (ie SD = 24 weeks with the 2 week RECIST assessment time window allowed). The Clinical Benefit Rate is the percentage of patients with CB.

Time frame:
every 12 weeks(+/- 2 weeks) from randomization to data up to data cut-off, 19th March 2008.
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Clinical Benefit Rate (CBR)42.254.946.8
SecondaryPharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body

The measure of dispersion for mean population clearance is based on the estimated inter-individual variance

Time frame:
Baseline to 12 weeks
Reported as:
Mean · L/h
Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body
L/hFulvestrant
Pharmacokinetic Parameter: Mean Population Clearance, a Measure of the Efficiency With Which Fulvestrant is Eliminated From the Body34.4 ± 0.096
SecondaryPharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes

The measure of dispersion for volume of distribution is based on the inter-individual variance estimated for the apparent volume of plasma into which Fulvestrant distributes

Time frame:
Baseline to 12 weeks
Reported as:
Mean · Vss/F (L)
Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes
Vss/F (L)Fulvestrant
Pharmacokinetic Parameter: Mean Volume of Distribution at Steady State, a Measure of the Apparent Volume in the Body Into Which Fulvestrant Distributes35300 ± 0.175

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant 250 mg—2/45 (4.4%)44/45 (97.8%)
Fulvestrant 250 mg + Loading Dose—5/51 (9.8%)49/51 (96.1%)
Fulvestrant 500 mg—1/46 (2.2%)44/46 (95.7%)
Most frequent serious events
Most frequent serious events
EventFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
Brain Stem InfarctionNervous system disorders1/450/510/46
Herpes ZosterInfections and infestations1/450/510/46
DizzinessNervous system disorders0/450/511/46
Back PainMusculoskeletal and connective tissue disorders0/451/510/46
Cardiac Failure CongestiveCardiac disorders0/451/510/46
Diverticular PerforationGastrointestinal disorders0/451/510/46
Fallopian Tube CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/451/510/46
FibromaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/451/510/46
Optic NeuritisNervous system disorders0/451/510/46
Most frequent other events
Showing 10 of 32
Most frequent other events
EventFulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mg
NasopharyngitisInfections and infestations17/4515/5116/46
Injection Site PainGeneral disorders14/4511/5114/46
NauseaGastrointestinal disorders11/459/516/46
Injection Site IndurationGeneral disorders9/456/5110/46
Hot FlushVascular disorders8/4511/517/46
HeadacheNervous system disorders3/458/514/46
FatigueGeneral disorders7/457/517/46
ArthralgiaMusculoskeletal and connective tissue disorders2/457/512/46
ConstipationGastrointestinal disorders4/457/515/46
PyrexiaGeneral disorders2/454/515/46

Baseline characteristics

Age Continuous
Age Continuous(Years)Fulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mgTotal
Mean62.5 ± 7.462.4 ± 9.562.7 ± 9.162.5 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant 250 mgFulvestrant 250 mg + Loading DoseFulvestrant 500 mgTotal
Female455147143
Male0000
08

Study locations

35 sites
  • Research Site
    Nagoya, Aichi, Japan
  • Research Site
    Asahi, Chiba, Japan
  • Research Site
    Matsuyama, Ehime, Japan
  • Research Site
    Kitakyushu, Fukuoka, Japan
  • Research Site
    Kurume, Fukuoka, Japan
  • Research Site
    Daito, Fukushima, Japan
  • Research Site
    Koriyama, Fukushima, Japan
  • Research Site
    Ota, Gunma, Japan
  • Research Site
    Fukuyama, Hiroshima, Japan
  • Research Site
    Kure, Hiroshima, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Amagasaki, Hyogo, Japan
  • Research Site
    Matsubaracho, Kagoshima, Japan
  • Research Site
    Isehara, Kanagawa, Japan
  • Research Site
    Sagamihara, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Sendai, Miyagi, Japan
  • Research Site
    Kurashiki, Okayama, Japan
  • Research Site
    Izumisano, Osaka, Japan
  • Research Site
    Sakai, Osaka, Japan
  • Research Site
    Suita, Osaka, Japan
  • Research Site
    Ina, Saitama, Japan
  • Research Site
    Moroyama, Saitama, Japan
  • Research Site
    Shimotsuke, Tochigi, Japan
  • Research Site
    Chuo, Tokyo, Japan
  • Research Site
    Koto-ku, Tokyo, Japan
  • Research Site
    Chiba, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Hiroshima, Japan
  • Research Site
    Kawasaki, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Niigata, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Shizuoka, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Mar 2008 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2006
First posted
Mar 22, 2006
Start
Mar 2006
Primary completionActual
Mar 2008
CompletionActual
Feb 2012
Results first posted
Aug 29, 2011
Last update
Feb 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00305448
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 22, 2006
Start date
Mar 2006
Primary completion
Mar 2008
Completion
Feb 2012
Results posted
Aug 29, 2011
Last update
Feb 15, 2012

Study contacts

AstraZeneca Japan Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion